Navigation Links
Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
Date:9/28/2010

BONITA SPRINGS, Fla. and NEW YORK, Sept. 28 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced today that it has completed a private placement of Series C Convertible Preferred Stock resulting in gross proceeds of approximately $6.5 million.  The financing, which was led by Mr. Neil Flanzraich, also included current investors Wexford Spectrum Investors, LLC, and Sonostar Capital Partners, LLC and other institutional and individual investors.  Riverbank Capital Securities, Inc. acted as placement agent in connection with the financing.  

Tigris intends to use the proceeds from the financing primarily to advance the development of its clinical product pipeline, including its lead compound, Aminoflavone pro-drug (AFP-464), a novel anticancer agent.  A multi-center, Phase I, ascending dose clinical study of AFP-464 has been completed in Europe at Institut Gustave-Roussy, Villejuif, France and Jules Bordet Institute, Brussels, Belgium.  The company expects to initiate a multi-site phase II breast cancer study in 2010.  AFP-464's mechanism of action has shown that AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis.  AFP-464 has shown a unique pattern of growth inhibitory activity in the tumor cell line screening, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound.  In vivo antitumor activity of AFP-464 has been demonstrated in several Xenograft models in mice bearing breast and renal cancer.

Additionally, Tigris is currently conducting a multi-center Phase I dose escalation trial for GGTI-2418, another first-in-class agent, at Abramson Cancer Center at the University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center.  GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has ... (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava ... by 2016. The North America ... while Europe claims approximately 27% ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... Grifols, a global healthcare company and biopharmaceutical manufacturer based ... an Expert Advisory Council in Transfusion Medicine drawing on ... across the globe.  The role of the Expert Advisory ... Grifols, own transfusion medicine research and development activities. ...
... CareFusion Corporation (NYSE: CFN ... of Carlos M. Nunez, M.D. as its chief medical officer ... and hospitalist as well as an experienced health care technology ... the areas of clinical effectiveness, information technology, public policy and ...
Cached Medicine Technology:Grifols Establishes Expert Advisory Council in Transfusion Medicine 2Grifols Establishes Expert Advisory Council in Transfusion Medicine 3CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... all types of dementia, including Alzheimer,s disease, finds a new ... The study of more than 1,000 people in Japan found ... to 20 percent of people with normal blood sugar levels. ...
... with low sunlight are up to 3 times more ... should take high levels of Vitamin D supplements, according to ... "This study shows that the current one-size fits ... don,t work," said Adam Murphy, M.D., a clinical instructor in ...
... improvements in treating heart attack patients needing emergency artery-opening ... hospitals that can perform the procedure, according to a ... Association . Fast response is critical for ST-segment ... is caused by a complete blockage of blood supply ...
... (MEMPHIS, Tenn. September 19, 2011) The largest study ever ... the tumors carried extra copies of specific genes linked to ... Research Hospital investigators. The findings identify possible new ... as diffuse intrinsic pontine glioma (DIPG). Current survival rates for ...
... of boredom or fatigue, yawning might also be a ... by Andrew Gallup, a postdoctoral research associate in Princeton ... first involving humans to show that yawning frequency varies ... to yawn when the heat outdoors exceeds body temperature. ...
... MONDAY, Sept. 19 (HealthDay News) -- Obese 8- and ... their normal-weight peers, a new study finds. In the ... height and weight, at ages 4 and 5 and then ... questionnaires that assessed children,s mental health and health-related quality of ...
Cached Medicine News:Health News:More Evidence Links Diabetes, Dementia 2Health News:More Evidence Links Diabetes, Dementia 3Health News:One size doesn't fit all for vitamin D and men 2Health News:Emergency treatment for heart attack improving but delays still occur 2Health News:Emergency treatment for heart attack improving but delays still occur 3Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:More than a sign of sleepiness, yawning may cool the brain 2Health News:More than a sign of sleepiness, yawning may cool the brain 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: